As part of the £4.5m, eleven project initiative, this specific project will fund a consortium of five industrial and academic partners led by Unilever.
During the three year program of research, AmpliPhi Biosciences will exploit novel genomic information to develop next generation, specific, natural antimicrobials for use in the personal care industry.
AmpliPhi CEO Edward Cappabianca said they anticipate that the information they gain during the execution of this project will contribute significantly to their knowledge base of how to develop novel antimicrobial products for the general market, and in turn help to advance their development of human therapeutics to treat bacterial infections.